Hospital Universitario de Donostia-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2023

  1. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

    United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2018

  1. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

    Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819

2013

  1. Alopecia areata in a patient receiving infliximab

    Indian Journal of Dermatology, Venereology and Leprology

2002

  1. Tuberculosis, another cause of generalized lymphadenopathies in celiac disease

    Gastroenterología y hepatología